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It has been reported that IFN-γ,T N F - α, and IL-12 stimulate, and that IL-10, TGF-β, and IL-4 suppress the protective immune
response against tuberculosis. We aim to evaluate changes in the serum levels of pro and antiinﬂammatory cytokines in active
pulmonary tuberculosis (APTB) and the possible eﬀects of treatment on these changes. Serum IL-12p40, IL-4, IL-10, TNF-α,I F N -
γ,a n dT G F - β1 levels were determined in 20 APTB cases (group 1) before and 2, 4, and 6 months after therapy. The same parameters
were also determined in 9 inactive pulmonary tuberculosis (IPTB) cases (group 2) and 9 healthy controls (HC, group 3). Before
treatment, the mean serum IFN-γ,T N F - α, and IL-10 levels in group 1 were statistically higher than those in group 2 (P = .001,
P = .024, P = .016, resp) or group 3 (P = .003, P = .002, P = .011, resp). The levels in group 1 decreased signiﬁcantly after
treatment (P = .001 for IFN-γ, P = .004 for TNF-α, P = .000 for IL-10). The serum levels of IL-12p40 were signiﬁcantly higher
in group 1 than in group 3 (P = .012) and decreased insigniﬁcantly after treatment. There was no diﬀerence in serum IL-4 and
TGF-β1 levels among the groups (P>. 05). Because the serum IL-12p40, IL-10, TNF-α,a n dI F N - γ levels were high in APTB, we
believe that these cytokines have important roles in the immune response to Mycobacterium tuberculosis (M tuberculosis). These
parameters could be used in follow-up as indicators of the success of APTB therapy.
INTRODUCTION
Mycobacterium tuberculosis (M tuberculosis)i so n e
of the most widespread pathogens; it is estimated that
roughly one third of the world’s population is infected
with the bacillus and approximately 8–10 million people
become infected every year. It is responsible for 8–12 mil-
lion cases of active tuberculosis each year, and 3 million
deaths [1, 2, 3]. In Turkey, the incidence of disease was
31.5/100000 in 1997 and mortality rate was 2.1/100000
in 1996 [4].
The interaction of T cells with infected macrophages
is central to protective immunity against M tuberculosis
and depends on the interplay of cytokines produced by
each cell [5]. TNF-α, IL-12, and IFN-γ are central cy-
tokines in the regulatory and eﬀector phases of the im-
mune response to M tuberculosis [6]. T ˆ H1 cells and nat-
ural killer (NK) cells secrete IFN-γ,w h i c ha c t i v a t e sa l v e -
olar macrophages to produce a variety of substances in-
volved in growth inhibition and killing of mycobacteria.
Macrophages also secrete IL-12, amplifying this pathway
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in a positive feedback loop [1]. IL-12 has been implicated
in the pathogenesis of T-cell-mediated pathology because
it drives antigen-naive T ˆ H cells towards development into
T ˆ H1 cells [7]. TNF-α is believed to play multiple roles in
the immune and pathological responses in tuberculosis.
M tuberculosis induces TNF-α secretion by macrophages,
dendritic cells, and T cells [8]. The production of anti-
inﬂammatory cytokines such as IL-4, IL-10 and TGF-β
in response to M tuberculosis may down-regulate the im-
mune response and limit tissue injury, but excessive pro-
duction of these cytokines may result in failure to control
the infection [9].
Few researchers have studied changes in systemic cy-
tokine levels in patients with tuberculosis and these few
have obtained diﬀerent results. The aim of the present
study was to determine the serum concentrations of IL-
12p40,IL-4,IL-10,TNF-α,IFN-γ,andT GF -β1inpatients
with active and inactive pulmonary tuberculosis and to
compare these values with (a) those obtained from nor-
mal blood donors, and (b) those obtained from the pa-
tients after therapy.
MATERIAL AND METHODS
Thestudypopulationconsistedof20newlydiagnosed
APTB outpatients admitted to the Firat Medical Center
and Elazig Tuberculosis Dispensary (group 1; mean ± SD2005:5 (2005) Cytokine Levels in Tuberculosis 257
Table 1. Serum levels of cytokines in active pulmonary tuberculosis (APTB) cases, inactive pulmonary tuberculosis (IPTB) cases, and
healthy controls (HC).
Cytokines (pg/mL) APTB cases (n = 20) (baseline) IPTB cases (n = 9) HC (n = 9)
IL-12 p40 10.4 ±6.2a 7.3 ±3.25 .7 ±4.9a
IL-4 33.5 ± 2.63 2 .4 ±2.23 3 .9 ±1.9
IL-10 5.9 ±1.9bc 4.5 ±4.1b 3.6 ±2.0c
TNF-α 57.6 ±12.2de 49.8 ±10.3d 45.6 ±4.7e
IFN-γ 19.1 ±3.2fg 14.7 ±2.5f 15.8 ±5.3g
TGF-β1 258.1 ±306.6 185.1 ±216.5 110.3 ±83.2
aP = .012, bP = .016, cP = .011, dP = .024, eP = .002, fP = .001, gP = .003.
age = 38.70 ± 18.51, 9 men and 11 women). Diagnosis
of tuberculosis (TB) was based on clinical and radiolog-
ical data along with the identiﬁcation of tubercule bacilli
in sputum (at least one positive sputum smear and cul-
ture result for acid-fast bacilli). Acid-fast bacillus stain-
ing was performed by the Ziehl-Neelsen method. Mt u -
berculosis was cultured on L¨ owenstein-Jensen solid me-
dia. As ﬁrst line therapy, a standard antituberculous reg-
imen for nonresistant cases including INH, RMP, PZA,
and EMB or SM daily for 2 months and INH, RIF daily
for 4 months had been given to all the patients. Clinically
they all had mild disease and underwent uneventful re-
covery following chemotherapy. No extrapulmonary in-
volvement was found in any patient. Patients who had di-
abetes mellitus, pregnancy or immunological or autoim-
munediseasesotherthantuberculosiswereexcludedfrom
the study. None of the subjects had serological evidence of
HIV infection.
Nine IPTB cases that were registered and treated in
the Elazig Tuberculosis Dispensary (group 2; mean ± SD
age 35.67 ± 18.02, 4 men, 5 women) were also included,
and 9 healthy volunteer subjects living same area were in-
cluded as a control group (HC, group 3; mean ± SD age
33.70 ± 4.27, 3 men, 6 women). The IPTB patients had
a history of previous TB episodes with a positive culture
documented at the time of diagnosis. There were abnor-
mal stable radiographical ﬁndings and no changes had
beenobservedduringtheprevioussixmonths.Threespu-
tum cultures for M tuberculosis were negative in all the
IPTB patients [10].
Tuberculin testing was performed by the Mantoux
test: 5 IU PPD (BB-NCIPD Ltd, Sophia, Bulgaria) was in-
jected intradermally into the volar surface of the forearm
and the results were evaluated 72 hours later. A transverse
induration of ≥10mm was considered positive. All APTB
and IPTB patients were positive on the PPD skin test. The
healthy subjects had been vaccinated with BCG as part of
the obligatory Turkey National Vaccination Program and
a l lw e r et u b e r c u l i np o s i t i v e .
Venous blood samples (5mL) were taken from all
controls (baseline only) and from the APTB patients at
baseline,thatis,beforestartingantituberculosistreatment
(ATT), and after 2, 4, and 6 months of ATT. The blood
sampleswerecentrifugedat5000rpmfor10minutes;sera
were collected and stored at −80◦C until they were as-
sayed. IL-12p40, IL-4, IL-10, TNF-α,T G F - β1, IFN-γ lev-
els were measured simultaneously in all serum samples
by ELISA, following the manufacturer’s instructions on a
commercial kit (Medgenix, Biosource International, Ca-
marillo, USA).
Informed consent was obtained from all subjects.
Statisticalanalysis
Statistical analysis was performed using SPSS 12.0
packet software. The data were expressed as arithmetic
means with standard deviations; P<. 05 was consid-
ered statistically signiﬁcant. Diﬀerences in cytokine levels
among groups were evaluated by the Kruskal-Wallis and
Mann-Whitney U tests. Diﬀerences in group 1 cytokine
levels between diﬀerent treatment stages were evaluated
by paired-samples t tests.
RESULTS
There were no statistically signiﬁcant age or gender
diﬀerences among the groups. The mean PPD response
was statistically higher in the APTB (14.9 ± 2.3mm) and
IPTB (14.7±1.7mm) cases than the HC (12.2±2.2mm)
(P = .011 for APTB and P = .025 for IPTB compared
with HC).
The serum IL-12p40, IL-4, IL-10, TNF-α,I F N - γ,a n d
TGF-β1 levels in the APTB and IPTB cases and HC are
shown in Table 1.
The mean serum IL-10, TNF-α,a n dI F N - γ levels were
signiﬁcantly higher in the APTB than the IPTB cases (P =
.016, P = .024, P = .001, resp) or the HC (P = .011, P =
.002,P = .003,resp).Therewerenosigniﬁcantdiﬀerences
in serum IL-4 and TGF-β1 levels among the groups (P>
.05).ThemeanserumlevelsofIL-12p40weresigniﬁcantly
higher in the APTB cases than HC (P = .012) (Table 1).
Figure 1b shows that the mean serum IL-10 level de-
creased signiﬁcantly in group 1 patients after antitubercu-
lous therapy (ATT) for 4 (3.5 ± 2.1pg/mL)and6(3.5 ±
1.7pg/mL) months (baseline level 5.9 ± 1.9pg/mL)(P =
.018, P = .000, resp). Thesame wastrueof TNF-α (Figure
1a); the levels after 4 and 6 months were 48.5 ± 12.2258 Figen Deveci et al 2005:5 (2005)
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Figure 1.Themeanserumlevelsof(a)IL-12andTNF-αand(b)IL-10andIFN-γ inAPTBpatients(n = 20).Na¨ ıve:patientswhohad
not received ATT. 2T: patients who received ATT for two months. 4T: patients who received ATT for four months. 6T: patients who
received ATT for six months. aSigniﬁcantly diﬀerent compared with 4T (P = .034 for TNF-α, P = .018 for IL-10) and 6T (P = .004
for TNF-α, P = .000 for IL-10) patients. bSigniﬁcantly diﬀerent compared with 2T (P = .008), 4T (P = .000), and 6T (P = .001).
and 49.2 ± 4.9pg/mL, respectively; the level before ther-
apy was 57.6 ± 12.2pg/mL(P = .034, P = .004, resp).
Also, the serum IFN-γ levels decreased in the APTB pa-
tients after 2 (16.6±1.9pg/mL),4(14.7±1.8pg/mL),and
6( 1 4 .5 ± 3.4pg/mL) months of therapy (Figure 1b); the
baseline value was 19.1 ± 3.2pg/mL(P = .008, P = .000,
P = .001, resp). There were no signiﬁcant diﬀerences in
these parameters between patients who received ATT for
6 months and HC (P>. 05). Treatment eﬀected no sig-
niﬁcant diﬀerences in IL-4 and TGF-β1l e v e l s( P>. 05).
The decrease in serum IL-12p40 levels during therapy was
insigniﬁcant (Figure 1a).
DISCUSSION
We found signiﬁcantly raised serum levels of IL-10,
IL-12p40, TNF-α,a n dI F N - γ in patients with APTB.
Therapy aﬀected statistically signiﬁcant decreases in the
concentrations of all these cytokines except IL-12p40.
Previous studies of stimulated peripheral blood
mononuclear cells (PBMNC) or CD4+ Tc e l l sf r o mT B
patients showed increased, unchanged, or decreased cy-
tokine production [11, 12, 13]. TNF-α is produced at the
site of disease in tuberculosis patients [14]. Early clinical
deterioration in treatment is associated with a selective
increase of TNF-α in plasma [15]. In particular, patients
with PTB accompanied by systemic manifestations (per-
sistent fever, weight loss) showed increased TNF-α and
IL-10 and decreased IL-12 levels compared with controls
[16]. IL-12, which is mediated by IL-10, has a role in host
defenseagainstMtuberculosisandisessentialforinducing
IFN-γ production [17]. One study showed that the TNF-
α and IFN-γ levels were raised in PBMNC from patients
stimulated with the 30-kd antigen of M tuberculosis com-
paredtocontrols,buttherewasnodiﬀerenceinIL-10lev-
els [18]. However, no signiﬁcant diﬀerences were found
in the number of IFN-γ producing lymphocytes when
PBMNC from tuberculosis patients and healthy contacts
werestimulated invitrowithMtuberculosis antigens [19].
InpatientswithadvancedstagesofPTB,the30-kdantigen
of M tuberculosis induces increased production of IL-10
and decreased production of IFN-γ by PBMNC [20]. In-
c r e a s e dl e v e l so fI L - 1 0a n dT G F - β have been reported in
serafromTBpatients,andinvitroIL-10andTGF-βsecre-
tion by the PBMNC and/or monocytes is increased in TB
patients in response to Mtuberculosis antigens [21].In the
study by Lee et al, there was no statistically signiﬁcant dif-
ference in IL-12p40 production between newly diagnosed
pulmonary TB and healthy tuberculin reactors (HTR) af-
ter in vitro stimulation with antigens [22]. Several studies
have described altered IL-12 after M tuberculosis infection
in TB patients at various clinical stages. The IL-12 level is
relatively high in patients with advanced pulmonary TB
who produce low levels of IFN-γ compared to moderate
c a s e so rH T R s[ 23]. A greater increase in IL-12 was seen
in TB patients than in healthy donors in peripheral blood
stimulated by mycobacteria [24].
Diﬀerences among reports of systemic cytokine bal-
ance in TB patients based on in vitro stimulation studies
might be attributable to diﬀerences in isolation and cul-
ture techniques, or in the stimulus used, and may not re-
ﬂect the actual situation in vivo [25, 26]. Previous studies2005:5 (2005) Cytokine Levels in Tuberculosis 259
have shown higher serum levels of TNF-α in pulmonary
TB patients than control subjects [27, 28, 29, 30]. Also,
serum TNF-α levels were signiﬁcantly higher in both ac-
tive and inactive TB patients than healthy controls, and
signiﬁcantly higher in active than inactive TB patients
[31]. Furthermore, increased TNF-α has been reported in
early stages of TB, and this extends to plasma from con-
tacts of pulmonary TB patients who are suspected of be-
ing in early stages of TB infection but are not TB patients
[32]. Our results agree with above reports in that serum
TNF-α levels are elevated in APTB patients compared to
IPTB patients and controls.
The study by Dlugovitzky et al demonstrated that the
serum levels of IFN-γ were increased in patients with
PTB, especially in mild and moderate TB cases com-
p a r e dt oa d v a n c e dT B[ 26]. There is in vitro evidence
that TB patients with progressive disease fail to gener-
ate IFN-γ in response to stimulation with mycobacte-
rial antigens [33, 34]. Other studies that evaluated serum
IFN-γ levels in TB patients showed increases relative to
c o n t r o ls u b j e c t s[ 28, 35, 36]. According to our results
and others, IFN-γ is an important cytokine in T ˆ H1-
mediated cellular immunity. T lymphocyte activation fol-
lowing mycobacterial antigen recognition on antigen pre-
senting cells induces a variety of responses in CD4+
T ˆ H1 cells, including cytotoxic activity against infected
macrophagesandsynthesisofIFN-γ.I nturn,IFN-γ stim-
ulates human macrophages to produce TNF-α and 1,25-
dihydroxyvitamin D, both of which facilitate mycobacte-
rial inhibition [37, 38, 39].
Mycobacterial products induce the production of
TGF-β by monocytes and dendritic cells; TGF-β is pro-
duced in excess during TB and is expressed at the site of
disease [40, 41]. It suppresses cell-mediated immunity; in
T cells, it inhibits proliferation, IFN-γ production, and
proinﬂammatory cytokine production, and it is known
to counteract TNF-α production by monocytes [42, 43].
OnestudyofinvitrostimulationofPBMNshowedhigher
TGF-β,I F N - γ,a n dT N F - α levels in samples from TB pa-
tients than control subjects [23]. In addition, Fiorenza et
al [44] found increased levels of both TGF-β and TNF-
α in severe TB patients. While having some antiinﬂam-
matory eﬀects, excessive TGF-β in severe disease may also
have harmful consequences for host resistance because it
counteracts productive immune mechanisms against TB
[39]. In our study no diﬀerences in the serum TGF-β 1
levels were found between APTB patients on one hand
andIPTBpatientsorcontrolsontheother,althoughthere
was a signiﬁcantly increased level of TNF-α in the APTB
patients.TheseresultssuggestthatTGF-β1hasproinﬂam-
matory activity at low concentrations and antiinﬂamma-
tory activities at high concentrations. Similar results were
obtained by Olobo et al [32], who found signiﬁcantly ele-
vatedplasmalevelsofTGF-β butundetectableplasmalev-
els of TNF-α in TB patients. According to their interpre-
tation, the undetectable plasma levels of TNF-α may be
due to the purported suppressive eﬀect of TGF-β.O v e r -
all, the interactions of TNF-α and TGF-β are complex
and further studies are needed; cytokine responsiveness
and expression may be inﬂuenced by cell type and con-
text.
We found no signiﬁcant diﬀerences among groups in
the serum levels of IL-4. T ˆ H2 responses and IL-4 in TB
a r es u b j e c t so fs o m ec o n t r o v e r s y .S o m ep r e v i o u ss t u d i e s
have shown increased production of IL-4 in human TB
patients, especially those with cavitary disease [19, 45];
according to others, it still remains to be determined
whether IL-4 causes or merely reﬂects disease activity in
human TB [12, 46]. Some studies showed no detectable
IL-4inanyTBpatientandnosigniﬁcantdiﬀerenceinIL-4
levelbetweenTBpatientsandcontrols[11,25,41,47,48].
Increased levels of IL-10 have been found in TB patients
[25, 49, 50]. As expected, we found raised serum levels of
IL-10 in APTB compared to other groups. Studies eval-
uating the number of peripheral IL-12 producing cells,
as well as cytokine expression in lymph nodes or BAL,
showed elevated IL-12 production in TB patients [24, 51].
In contrast, one study [35] showed no diﬀerence in serum
IL-12 levels between TB patients and controls. Verbon
et al [25] demonstrated that serum IL-12p40 levels were
not signiﬁcantly diﬀerent between active TB and control
groups, and were signiﬁcantly lower in patients with than
those without a positive. In the present study, we found
that APTB patients had higher serum IL-12p40 than con-
trol subjects. We think that IL-12p40 plays a role in an-
timicrobial host defence. These reports suggest that an al-
tered balance between cytokines is implicated in TB dis-
ease,ratherthanelevationordecreaseofjustonecytokine
[25].
We aimed to evaluate serum cytokine levels in APTB
patients before and after therapy. Statistically signiﬁcant
reductions were found in both IL-10 and TNF-α levels
following 4 months of therapy, and in IFN-γ levels fol-
lowing 2 months of therapy, but no change in IL-12, IL-4,
or TGF-β1 levels. One study, which evaluated serum lev-
els of pro or antiinﬂammatory cytokines before and after
treatment in pulmonary TB patients, showed that IFN-
γ and TNF-α levels in BAL were decreased, IL-4 levels
were increased, and serum levels of IFN-γ,T N F - α,a n d
TGF-β1 were decreased [28]. Similarly, Tang et al [31]
and Kawaguchi et al [30] found decreased TNF-α levels
and Berktas et al [36] found decreased IFN-γ levels in
TB patients after therapy. The increased plasma TNF-α
level may be associated with the clinical deterioration ob-
served early in treatment of severe TB [15]. In a recent
study, TNF-α levels in sputum decreased following initia-
tion of ATT but serum TNF-α levels were unchanged af-
ter 12 weeks [52]. Kart et al [27] found that the increased
TNF-α levels were not changed after ATT and suggested
that TNF-α may be involved in delayed-type hypersensi-
tivity responses, although the levels were not correlated
with sequela and cavity formation in their cases and the
systemic cytokine responses were diﬀerent from the local
response to ATT. We believe that evaluating the serum cy-
tokine levels may be useful in evaluating the clinical eﬀect
of antituberculous therapy.260 Figen Deveci et al 2005:5 (2005)
In conclusion, proinﬂammatory cytokines play an es-
pecially important role in the pathogenesis of active pul-
monary tuberculosis. We show here that only one antiin-
ﬂammatory cytokine (IL-10) is elevated in the serum of
APTB patients. Measuring the serum levels of several cy-
tokinesmaybeusefulforevaluatingtheactivityofTBdis-
ease and monitoring the clinical eﬀect of antituberculous
treatment. Further studies are needed to address the role
of cytokines in immunity to TB under natural conditions.
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